Shares of Elite Pharmaceuticals, Inc. (ELTP) have lost 10.7% since the company reported its earnings for the quarter ended Dec. 31, 2025. This compares with the S&P 500 Index’s 0.2% gain over the same time frame. Over the past month, the stock plunged 16.3%, underperforming the broader market, as the S&P 500 fell 0.8% during that period.ELTP’s Earnings and Revenue PerformanceFor the third quarter of fiscal 2026, Elite Pharmaceuticals reported total revenues of $31.6 million, up 119.9% from $14.4 million in ...

Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter").Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared to the comparable period of the ...